The role of ventriculoperitoneal shunting in patients with supratentorial glioma

Authors

  • Macarena I. de la Fuente,

    1. Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York
    Search for more papers by this author
  • Lisa M. DeAngelis

    Corresponding author
    1. Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York
    • Correspondence

      Lisa M. DeAngelis, Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Tel: (212) 639-7997; Fax: (212) 717-3296; E-mail: deangell@mskcc.org

    Search for more papers by this author

Abstract

Objectives

To assess the impact of ventriculoperitoneal (VPS) in patients with glioma.

Methods

Retrospective review of patients with grade II-IV glioma who had VPS placement from January 1995 to November 2012.

Results

We identified 62 patients. At time of VPS, 41 had gait disturbance, 40 cognitive impairment and 16 urinary incontinence; 10 had the classic triad. Thirty-eight (61%) improved after VPS. Median overall survival from VPS was 7 months for all patients, but 11 months for those who improved and 2 months for non-responders. Leptomeningeal disease, glioma grade or radiographic ventricular decompression did not predict benefit.

Conclusions

VPS can improve functional status in some patients with symptoms suggestive of hydrocephalus.

Ancillary